Navigation Links
AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
Date:2/12/2008

QUEBEC CITY, Feb. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that dosing of AEZS-108, a luteinizing hormone-releasing hormone (LHRH) agonist linked to doxorubicin, has commenced in its Phase 2 trial in gynaecological cancers for which patient enrolment had begun in December 2007. This open-label, non-comparative multi-center Phase 2 trial will treat up to 82 women with LHRH-receptor positive ovarian and endometrial cancerous tumors. The primary endpoint for the trial will be the partial or complete tumor response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) and/or Gynaecologic Cancer Intergroup (GCIG) guidelines. The trial is being conducted in 15 centers in Europe under the supervision of lead investigator, Prof. Gunter Emons, M.D., of the Georg-August-University, Gottingen Institute of Gynaecology and Obstetrics in Gottingen, Germany.

David J. Mazzo, Ph.D., President and CEO of AEterna Zentaris commented, "We are excited to have started dosing patients in our Phase 2 trial with AEZS-108, our highest priority oncology compound. We believe that our approach targeting only patients with LHRH-receptor expressing tumors using doxorubicin is key to both potential increased individual patient safety and potential augmented clinical benefit, while ultimately providing us results that will be pivotal in formulating the next steps in the clinical development of this novel agent."

About the Phase 2 trial

Entitled, "The antitumoral activity and safety of AEZS-108 (AN-152), a LHRH agonist linked doxorubicin in women with LHRH-receptor positive gynaecological tumors", this Europe
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
2. AEterna Zentaris Announces Outcome of Managements Strategic Review
3. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
4. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
5. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
6. Immtech Reports Fiscal Third Quarter 2008 Results
7. Phlo Affiliate Reports Progress in New York City Metropolitan Area Roll-Out
8. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
9. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
10. Bunge Reports Fourth Quarter Net Income of $245 Million
11. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Paul, Minnesota (PRWEB) September 19, 2014 ... from related food industries will gather October 5–8, ... at the Rhode Island Convention Center in Providence, ... will feature the work of food scientists, chemists, ... quality control, and food production management. To date, ...
(Date:9/18/2014)... HealthTronics, Inc ., a ... products and services, announced that a poster related ... versus external beam radiotherapy (EBRT) is being presented ... Association (MAAUA) Annual Meeting in Baltimore, Maryland September ... Cryosurgery and External Beam Radiation as Treatments for ...
(Date:9/18/2014)... , September 18, 2014 ... ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the ... - Global Strategic Business Report" ... http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the worldwide ... Million by the following Product Segments: ...
(Date:9/18/2014)... Research and Markets has announced ... Report 2014" report to their offering. ... a professional and in-depth study on the current state ... report provides a basic overview of the industry including ... albumin market analysis is provided for the international markets ...
Breaking Biology Technology:Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3
... 27 DHA omega-3 innovator,Martek Biosciences announced today that ... featured in new Ricos(R) Cheese Sauce.,Sold to schools throughout ... of,DHA per serving in the standard foodservice packaging of ... 3.5 oz. single serve cup which contains 50 mg,of ...
... III Development and ... -, NEW YORK, and PRINCETON, N.J., Aug. 27 ... Company (NYSE: BMY ) ("companies"),today announced that they ... research, develop and commercialize DGAT-1,inhibitors, a collaboration first announced ...
... launched today a new 200 mg single-use vial ... who have,adjuvant stage III colon cancer and advanced ... efficiency and safety in the,preparation of the injectable ... mg and 100 mg single- use vials. The ...
Cached Biology Technology:life'sDHA(TM) Featured in New Ricos(R) Cheese Sauce 2life'sDHA(TM) Featured in New Ricos(R) Cheese Sauce 3Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program 2Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program 3Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program 4New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 2New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 3New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 4New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 5New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 6New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 7
(Date:9/18/2014)... millions of Americans to undertake jaunts into the countryside each ... longer within a century, according to new research. , Climate ... the United States as summer temperatures linger later into the ... Ecology and Biogeography . For instance, the paper birch ... New Hampshire could change color one to three weeks ...
(Date:9/18/2014)... 18, 2014 -- Arizona turned its newborn screening program into ... short months, earning it the first-ever Newborn Screening Quality Award ... Dimes presented Will Humble, M.P.H., Arizona,s Department of Health Services ... Mr. Humble established a policy of full transparency for the ... blood samples to the lab for analysis, and set a ...
(Date:9/18/2014)... which have devastated algal forests in the eastern Mediterranean ... basin if their distribution continues to expand as the ... an international team of researchers led by Dr Adriana ... the Mediterranean Institute for Advanced Studies in Spain, is ... of the team surveyed more than 1000 kilometres of ...
Breaking Biology News(10 mins):Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3Tropical fish a threat to Mediterranean Sea ecosystems 2
... A new cheetah study by the Wildlife Conservation Society and ... litters have more than one father. While promiscuity in ... the Wildlife Conservation Society and the Zoological Society of London ... with the wandering eye, as reported in a paper in ...
... new species of aeolid nudibranchs discovered in the ... discrete biogeographic region that has an extremely high ... to yield a wealth of never-before-described marine animals ... Institute in Panama. Alicia Hermosillo, researcher at the ...
... a significantly faster rate than projected by even the ... research, by scientists at the National Center for Atmospheric ... and Ice Data Center (NSIDC), shows that the Arctic's ... any of the 18 computer models used by ...
Cached Biology News:Philandering female felines forgo fidelity 2Scientists discover 5 new species of sea slugs from the Tropical Eastern Pacific 2Arctic ice retreating more quickly than computer models project 2Arctic ice retreating more quickly than computer models project 3
... Target Retrieval Solution, High pH This ... target retrievel prior to immunohistochemical staining procedures. ... tissue sections mounted on glass slides. For ... 9.9, is especially effective. It should be ...
... very potent Rnase free Ribonuclease ... a broad range of temperatures ... does not inhibit SP6, T7, ... and M-MLV reverse transcriptase or ...
... Dako Target Retrieval Solution, pH 9 ... Tris/EDTA buffer, pH 9, intended for heat-induced ... It is well-suited for use on formalin-fixed, ... Compared with 0.01 mol/L citrate buffer, pH ...
... SeMet White to off-white solid. Increases ... by HPLC. Soluble in H 2 O. ... to use. RTECS EK7713840, CAS 3211-76-5, M.W. ... 13, 8515.Jornot, L., and Junod, A.F. 1995. ...
Biology Products: